Deletion of PTPN22 improves effector and memory CD8+ T cell responses to tumors

Area of Science:

• Immunology
• Cancer Therapy
• Cellular Biology

Background:

• Adoptive T cell therapy (ACT) is an effective cancer treatment.
• Enhancing T cell function, recognition, and longevity is crucial for improving ACT.
• Previous work identified targeting phosphotyrosine phosphatase (PTPN) 22 in effector CD8+ T cells as a strategy to boost ACT efficacy in mice.

Purpose of the Study:

• To investigate the role of PTPN22 in effector and memory T cell responses during ACT.
• To determine if PTPN22 deficiency impacts anti-tumor activity and long-term T cell persistence.
• To assess PTPN22 as a target for optimizing ACT for cancer treatment.

Main Methods:

• Adoptive T cell therapy (ACT) was employed in mouse models.
• Comparison of PTPN22-deficient effector CD8+ T cells versus wild-type cells.
• Analysis of T cell persistence, anti-tumor activity against low-affinity antigens, and memory cell formation.

Main Results:

• PTPN22-deficient effector CD8+ T cells provided enhanced protection against tumors with low-affinity antigens.
• However, these PTPN22-deficient effector T cells exhibited reduced long-term in vivo survival.
• ACT using memory phenotype cells improved T cell persistence post-tumor clearance, with PTPN22-deficient T cells showing comparable memory formation but enhanced anti-tumor and effector responses.

Conclusions:

• PTPN22 plays a critical role in regulating effector and memory T cell dynamics during ACT.
• While PTPN22 deficiency enhances immediate anti-tumor responses, it impairs long-term T cell persistence.
• Targeting PTPN22 presents a promising strategy to improve both the efficacy and longevity of T cells in ACT for cancer therapy.